Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma

Conclusions: AlloSCT can produce durable remissions in a subset of patients with heavily treated, rel/ref PMBCL. Patients with refractory disease at alloSCT had dismal outcomes. Despite the expanding treatment options available for these patients, alloSCT should be considered in the management of patients with rel/ref PMBCL who are sensitive to salvage therapy.Figure 1A PFS and OS After AlloSCT in Patients with Rel/Ref PMBCLFigure 1B PFS in Patients with Sensitive versus Refractory PMBCL at AlloSCTDisclosuresHerrera: Merck, Inc.: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; AstraZeneca: Research Funding; Gilead Sciences: Research Funding; KiTE Pharma: Consultancy, Research Funding; Immune Design: Research Funding; Seattle Genetics: Research Funding; Pharmacyclics: Consultancy, Research Funding. Maloney: Roche/Genentech: Honoraria; GlaxoSmithKline: Research Funding; Juno Therapeutics: Research Funding; Seattle Genetics: Honoraria; Janssen Scientific Affairs: Honoraria. Ho: Jazz Pharmaceuticals: Consultancy. Soiffer: Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees. Antin: Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees. Forman: Mustang Therapeutics: Other: Licensing Agreement, Patents & Royalties, Research Funding. Chen: Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees; RE...

Source: Blood - November 21, 2018 Category: Hematology Authors: Herrera, A. F., Chen, L., Khajavian, S., Chase, M. L., Darrah, J., Maloney, D. G., Ho, V. T., Soiffer, R. J., Antin, J. H., Forman, S. J., Nademanee, A. P., Chen, Y.-B., Armand, P., Shadman, M. Tags: 732. Clinical Allogeneic Transplantation: Results: Poster I Source Type: research